DeepMed Research

Pegaptanib

Generic Name: Pegaptanib

Drug Type: Biotech

CAS Number: 222716-86-1

Unique Ingredient Identifier: 3HP012Q0FH

Background: Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability.

Pegaptanib was granted FDA approval on 17 September 2004.

Indication: For the treatment of neovascular (wet) age-related macular degeneration.

Associated Conditions: Neovascular Age-Related Macular Degeneration (nAMD)

Clinical Trials

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

Phase 3

Withdrawn

Conditions: Proliferative Diabetic Retinopathy

Interventions: Drug: Sham
Drug: Macugen

First Posted Date: 2012-05-02

Last Posted Date: 2014-03-05

Lead Sponsor: Greater Houston Retina Research

Registration Number: NCT01589718

Locations: 🇺🇸
Retina Consultants of Houston, Houston, Texas, United States

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

Phase 4

Completed

Conditions: Age-Related Macular Degeneration
Retinal Vein Occlusion
Diabetic Macular Edema

Interventions: Drug: pegaptanib sodium injection

First Posted Date: 2012-04-09

Last Posted Date: 2021-01-08

Lead Sponsor: Bausch & Lomb Incorporated

Target Recruit Count: 131

Registration Number: NCT01573572

Locations: 🇺🇸
Wolfe Eye Clinic, Marshalltown, Iowa, United States
🇺🇸
Valley Retina Institute, Harlingen, Texas, United States
🇺🇸
Marietta Eye Clinic, Murrieta, California, United States

and more 1 locations

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

Phase 4

Completed

Conditions: Diabetic Macular Edema

Interventions: Drug: Macugen® pegaptanib sodium

First Posted Date: 2011-12-06

Last Posted Date: 2013-07-16

Lead Sponsor: Valley Retina Institute

Target Recruit Count: 72

Registration Number: NCT01486238

Locations: 🇺🇸
Valley Retina Institute,PA, McAllen, Texas, United States

Prospective, Randomized, Open Label, Phase II Study to Assess Efficacy and Safety of Macugen® (Pegaptanib 0.3 mg Intravitreal Injections) Plus Panretinal Photocoagulation and PRP (Monotherapy) in the Treatment With High Risk PDR.

Phase 2

Completed

Conditions: High Risk Proliferative Diabetic Retinopathy
Diabetes Mellitus Type I
Diabetes Mellitus Type II

Interventions: Procedure: Panretinal Photocoagulation (PRP)
Drug: Intravitreous injection of pegaptanib

First Posted Date: 2011-01-21

Last Posted Date: 2015-03-19

Lead Sponsor: Association for Innovation and Biomedical Research on Light and Image

Target Recruit Count: 22

Registration Number: NCT01281098

Locations: 🇵🇹
Center for Clinical Trials - Aibili, Coimbra, Portugal

Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration

Completed

Conditions: Macular Degeneration
Age-related Macular Degeneration
Neovascular Macular Degeneration

Interventions: Drug: Pegaptanib

First Posted Date: 2010-11-22

Last Posted Date: 2011-01-13

Lead Sponsor: Pfizer

Target Recruit Count: 1001

Registration Number: NCT01245387

Intravitreal Pegaptanib in Treatment of Choroidal Neovascularisation Secondary to Pathologic Myopia

Not Applicable

Withdrawn

Conditions: Myopic Choroidal Neovascular Membrane

Interventions: Drug: Intravitreal Pegaptanib

First Posted Date: 2010-10-11

Last Posted Date: 2015-09-02

Lead Sponsor: L.V. Prasad Eye Institute

Registration Number: NCT01218230

Locations: 🇮🇳
LV Prasad Eye Institute, Hyderabad, AP, India

Study To Evaluate Safety And Tolerability Of Pegaptanib Sodium In Patients With Diabetic Macular Edema

Phase 3

Completed

Conditions: Anti- VGF Inhibitor
Diabetic Macular Edema
Diabetic Retinopathy

Interventions: Drug: pegaptanib sodium

First Posted Date: 2010-08-26

Last Posted Date: 2013-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT01189461

Locations: 🇪🇸
Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
🇸🇪
Ogonkliniken, Centrallasarettet, Vasteras, Sweden
🇬🇧
Kings College Hospital, London, United Kingdom

and more 9 locations

A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema

Phase 3

Completed

Conditions: Macular Edema
Diabetic Mellitus
Retinal Disease

Interventions: Other: sham injection
Drug: pegaptanib sodium

First Posted Date: 2010-04-08

Last Posted Date: 2013-08-23

Lead Sponsor: Pfizer

Target Recruit Count: 243

Registration Number: NCT01100307

Locations: 🇯🇵
Kohnan Hospital, Kobe, Hyogo, Japan
🇯🇵
Nihon University Surugadai Hospital, Chiyoda-ku, Tokyo, Japan
🇯🇵
Shiga University of Medical Science Hospital, Otsu, Shiga, Japan

and more 40 locations

Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.

Completed

Conditions: Neovascular Age-related Macular Degeneration

Interventions: Drug: pegaptanib sodium

First Posted Date: 2009-03-09

Last Posted Date: 2012-04-11

Lead Sponsor: Pfizer

Target Recruit Count: 86

Registration Number: NCT00858208

Locations: 🇬🇷
Pfizer Investigational Site, Xanthi, Greece

Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration

Completed

Conditions: Macular Degeneration

Interventions: Drug: Pegaptanib sodium

First Posted Date: 2009-02-18

Last Posted Date: 2015-10-02

Lead Sponsor: Pfizer

Target Recruit Count: 3538

Registration Number: NCT00845273

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy